{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:33:07Z","timestamp":1759411987427},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/coc.0b013e31827def82","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T18:30:15Z","timestamp":1361471415000},"page":"467-472","source":"Crossref","is-referenced-by-count":23,"title":["Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma"],"prefix":"10.1097","volume":"37","author":[{"given":"Travis E.","family":"Grotz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Kottschade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S.","family":"Pavey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":". Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/CMR.0b013e32834e1f33","article-title":". Regional lymphatic immunity in melanoma.","volume":"22","author":"Grotz","year":"2012","journal-title":"Melanoma Res"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":". Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.","volume":"102","author":"Mocellin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.3083507","article-title":". Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.","volume":"232","author":"Grabstein","year":"1986","journal-title":"Science"},{"key":"R5-9-20210128","first-page":"4086","article-title":". Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages.","volume":"49","author":"Thomassen","year":"1989","journal-title":"Cancer Res"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.182.4.1111","article-title":"Identification of dendritic cell colony-forming units among normal human CD34 bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocytemacrophage colony-stimulating factor and tumor necrosis factor alpha.","volume":"182","author":"Young","year":"1995","journal-title":"J Exp Med"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1182\/blood.V87.11.4520.bloodjournal87114520","article-title":". Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate.","volume":"87","author":"Szabolcs","year":"1996","journal-title":"Blood"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.4049\/jimmunol.154.11.5851","article-title":"Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34 bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha.","volume":"154","author":"Szabolcs","year":"1995","journal-title":"J Immunol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0092-8674(00)81926-1","article-title":". Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma.","volume":"88","author":"Dong","year":"1997","journal-title":"Cell"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":". Research electronic data capture (REDCap)a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","article-title":". Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.","volume":"18","author":"Spitler","year":"2000","journal-title":"J Clin Oncol"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CJI.0b013e3181a7d60d","article-title":". Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.","volume":"32","author":"Spitler","year":"2009","journal-title":"J Immunother"},{"key":"R13-9-20210128","first-page":"15","article-title":". GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.","volume":"19","author":"Elias","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CMR.0b013e32834640c0","article-title":". Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.","volume":"21","author":"Block","year":"2011","journal-title":"Melanoma Res"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/cbr.2007.0438","article-title":". Sequential administration of GM-CSF (Sargramostim) and IL-2autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.","volume":"23","author":"Elias","year":"2008","journal-title":"Cancer Biother Radiopharm"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e31827def82","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:50:26Z","timestamp":1714989026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201410000-00009"}},"subtitle":["A Single-center Study"],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31827def82","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}